期刊文献+

帕瑞昔布钠复合吗啡对腹部手术患者自控镇痛及呼吸功能的影响 被引量:2

Effects of analgesia with parecoxib combined morphine on patient controlled analgesia and pulmonary function in patients after abdominal opertion
下载PDF
导出
摘要 目的:观察帕瑞昔布钠复合吗啡对拟行腹部手术患者自控镇痛及呼吸功能的影响。方法:将50例拟行腹部手术患者随机分为帕瑞昔布钠组(P组)和吗啡组(M组),每组25例。PCA泵的镇痛药为吗啡1 mg/mL,应用PCA泵的同时,P组静脉注射首剂帕瑞昔布钠40 mg,首剂药物后12、24和36 h,静脉注射帕瑞昔布钠40 mg;M组在4时间点均注射生理盐水。镇痛开始后12、24、36和48 h记录疼痛VAS评分及镇静程度评分;PCA需求按压次数、有效按压次数及药物用量;术后各种并发症及不良反应发生率;术后24、48和72 h呼吸功能指标。结果:P组患者各时间点安静痛和咳嗽痛评分显著低于M组(P<0.05);镇静程度评分、PCA需求按压次数、有效按压次数及药物用量P组显著低于M组(P<0.05);P组恶心发生率显著低于M组(P<0.05);P组术后24、48 h的FVC%和FEV1%明显高于M组(P<0.05),术后24 h动脉血二氧化碳分压(PaCO2)明显低于M组(P<0.05)。结论:帕瑞昔布钠可安全有效地应用于拟行腹部手术患者自控镇痛,可减少吗啡用量并有利于呼吸功能恢复。 AIM: To investigate effects of an-algesia with parecoxib combined morphine on patient controlled analgesia and pulmonary func tion in patients after abdominal opertion. METHODS: Fifty patients were randomly alloca-ted to Parecoxib group (group P, n=25) and Morphine group (group M, n=25). Both groupreceived PCA with morphine (1 mg/mL) Group P received intravenous parecoxib 40 mg while the PCA pump beginning, 12,24 and 48 h after the first dose. Group M received intrave-nous normal saline at the same four point. The following indexes were recorded at 12, 24, 36 and 48 hours after the PCA pumps were used:VAS scores of pain, sedation score, demanded delivery, effective delivery, drug dose, and side effects. To compare parameters of pulmonary function in postoperative 24, 48 and 72 h be-tween the two groups. RESULTS. Compared with group M , there were significant decreases in VAS scores of pain at 12, 24, 36 and 48 hours after the PCA pumps were used(P〈0.05). Se-dation score, demanded delivery, effective deliv-ery and drug dose in group P were obviously lower than those in group M(P〈0.05). The in-cidence rate of nausea in group P was obviously lower than that in group M(P〈0.05). FVC% and FEV1% were significantly higher in postop-erative 24 and 48 h in treatment group than those in control group (P(0.05). PaCO2 were significantly lower in postoperative 24 h in treat-ment group than that in control group (P〈0.05). CONCLUSION: Parecoxib can relief painin patient after abdominal opertion safely and ef ficiently, reduce the morphine consumption and improve pulmonary function.
出处 《中国临床药理学与治疗学》 CAS CSCD 2011年第3期308-312,共5页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 帕瑞昔布钠 吗啡 疼痛 患者控制 呼吸 功能 Parecoxib Sodium Morphine Analgesia, patient-controlled Pulmonary func-tion
  • 相关文献

参考文献9

  • 1Apfelbaum JL, Desjardins PJ, Brown MT, et al. Multiple-day efficacy of parecoxib sodium treatment in postoperative bunionectomy pain[J]. Clin J Pain, 2008, 24(9): 784-792.
  • 2Viscusi ER, Gimbel JS, Halder AM, et al. A mul tiple-day regimen of parecoxib sodium 20 mg twice daily provides pain relief after total hip arthroplasty [J]. Anesth Analg, 2008, 107(2): 652-660.
  • 3Gierse JK, McDonald J J, Hauser SD, et al. A single amino acid difference between cyclooxygenase-1 (COX-1) and 2 (COX-2) reverses the selectivity of COX-2 specific inhibitors[J]. J Biol Chem, 1996, 271(26): 15810-15814.
  • 4赵晶,叶铁虎,罗爱伦.镇痛药物及其应用[J].中国临床康复,2002,6(16):2350-2352. 被引量:49
  • 5Hubbard RC, Naumann TM, Traylor L, et al Parecoxib sodium has opioid-sparing effects in pa tients undergoing total knee arthroplasty under spi nalanaesthesia[J].Br J Anaesth, 2003, 90(2) 166-172.
  • 6Gross JB. Parecoxib sodium, a parenteral cyclooxy genase-2 selective inhibitor, improves morphine analgesia and is opioid-sparing following total hip ar throplasty[J]. Surv Anesthesiol, 2004, 48(2):99 -100.
  • 7吴新民,岳云,张利萍,王俊科,艾登滨,于布为,薛张纲,黄文起.术后镇痛中帕瑞昔布钠对吗啡用量的节俭作用和安全性—前瞻性、多中心、随机、双盲、安慰剂对照、平行分组研究[J].中华麻醉学杂志,2007,27(1):7-10. 被引量:367
  • 8施文,王永铭,程能能,陈斌艳,李端.非甾体类抗炎药的不良反应研究进展[J].中国临床药理学杂志,2003,19(1):57-62. 被引量:60
  • 9Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors pare- coxib and valdecoxib in patients undergoing coronary artery bypass surgery[J].J Thorac Cardiovasc Surg, 2003,125(6) :1481--1492.

二级参考文献53

  • 1[1]Lichtenstein D, Syngal S, Wlfe MM. Non-steroidal antiinflammatory drugs and the gastrointestinal tract. Arthritis Rherm,1995;38:1:5~18.
  • 2[2]Bjarnason I, Macpherson A, Somasundaram S, et al. Lower bowel toxicity of non-steroidal anti-inflammatory drugs. Lewis A: Non-steroidal Anti-Inflammatory Drugs, Mechanisms and Clinical Uses. New York: NY, Marcel Dekker, 1994;145~157.
  • 3[3]Marie R, Griffin, MD. Epidemiology of non-steroidal antiinflammatory drug-associated gastrointestinal injury. Am J Med.1998;104: 23~28.
  • 4[4]Fujiwara Y, Schmassman A, Arakawa T, et al. Indomethacin interferes with epidermal growth factor binding and proliferative response of KATO Ⅲ cells. Digestion, 1995;56:364~369.
  • 5[5]Henry D, Robertson J. Non-steroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales.Gastroenterology. 1993; 104:1083~ 1091.
  • 6[6]Fries JF, Williams CA, Michel BA et al. Nonsteroidal antiinflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med, 1991 ;91:213 ~222.
  • 7[7]Gutthamm SP, García LA, Raiford DS. Individual nonsteroidal anti-inflammatory drugs and the risk of hospitalization for upper gastrointestinal bleeding and perforation in saskatche wan: a nested case-control study. Pharmacoepidemiol Drug Safety. 1994;3:S63.
  • 8[8]Loeb DS, Talley NJ, Ahlquist DA, et al. Long-term non-steroidal anti-inflammatorydrug use and gastroduodenal injury: the role of Helicobacter pylori. Gastroenterology, 1992;102 :1899~1905.
  • 9[9]Langman MJS, Weil J, Wainwright P, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal antiinflammatory drugs. Lancet, 1994 ;34 3 :107 5-107 8
  • 10[10]Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. am J Med, 1999;106:13~23.

共引文献468

同被引文献16

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部